Research programme: respiratory therapeutics - Galleon Pharmaceuticals

Drug Profile

Research programme: respiratory therapeutics - Galleon Pharmaceuticals

Alternative Names: Apnoea therapeutics - Galleon Pharmaceuticals; GAL 054; GAL-054 Family; GAL-160; GALL 200

Latest Information Update: 13 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Galleon Pharmaceuticals
  • Class Nitroso compounds; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Apnoea
  • Research Respiratory insufficiency

Most Recent Events

  • 13 Oct 2014 Preclinical development is ongoing in USA
  • 06 Jan 2011 Preclinical development is ongoing in USA
  • 31 Mar 2010 Early research in Respiratory insufficiency in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top